Literature DB >> 28402624

Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.

Kimihiro Ito, Makoto Mitsunaga, Takashi Nishimura, Masayuki Saruta, Takeo Iwamoto, Hisataka Kobayashi1, Hisao Tajiri.   

Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a new class of molecular targeted cancer therapy based on antibody-photoabsorber conjugates and NIR light irradiation. Recent studies have shown effective tumor control, including that of human epidermal growth factor receptor 2 (HER2)-positive cancer, by selective molecular targeting with NIR-PIT. However, the depth of NIR light penetration limits its use. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab linked to the cytotoxic agent maytansinoid DM1. Here, we developed bifunctional antibody-drug-photoabsorber conjugates, T-DM1-IR700, that can work as both NIR-PIT and chemoimmunotherapy agents. We evaluated the feasibility of T-DM1-IR700-mediated NIR light irradiation by comparing the in vitro and in vivo cytotoxic efficacy of trastuzumab-IR700 (T-IR700)-mediated NIR light irradiation in HER2-expressing cells. T-IR700 and T-DM1-IR700 showed almost identical binding to HER2 in vitro and in vivo. Owing to the presence of internalized DM1 in the target cells, NIR-PIT using T-DM1-IR700 tended to induce greater cytotoxicity than that of NIR-PIT using T-IR700 in vitro. In vivo NIR-PIT using T-DM1-IR700 did not show a superior antitumor effect to NIR-PIT using T-IR700 in subcutaneous small-tumor models, which could receive sufficient NIR light. In contrast, NIR-PIT using T-DM1-IR700 tended to reduce the tumor volume and showed significant prolonged survival compared to NIR-PIT using T-IR700 in large-tumor models that could not receive sufficient NIR light. We successfully developed a T-DM1-IR700 conjugate that has a similar immunoreactivity to the parental antibody with increased cytotoxicity due to DM1 and potential as a new NIR-PIT agent for targeting tumors that are large and inaccessible to sufficient NIR light irradiation to activate the photoabsorber IR700.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28402624      PMCID: PMC7920516          DOI: 10.1021/acs.bioconjchem.7b00144

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  35 in total

1.  The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.

Authors:  Hans K Erickson; Gail D Lewis Phillips; Douglas D Leipold; Carmela A Provenzano; Elaine Mai; Holly A Johnson; Bert Gunter; Charlene A Audette; Manish Gupta; Jan Pinkas; Jay Tibbitts
Journal:  Mol Cancer Ther       Date:  2012-03-09       Impact factor: 6.261

2.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

3.  Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging.

Authors:  Takahito Nakajima; Kohei Sano; Makoto Mitsunaga; Peter L Choyke; Hisataka Kobayashi
Journal:  Cancer Res       Date:  2012-07-16       Impact factor: 12.701

4.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Authors:  M A Molina; J Codony-Servat; J Albanell; F Rojo; J Arribas; J Baselga
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

5.  Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.

Authors:  Kazuhide Sato; Hirofumi Hanaoka; Rira Watanabe; Takahito Nakajima; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Cancer Ther       Date:  2014-11-21       Impact factor: 6.261

6.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

Review 7.  Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy.

Authors:  Hisataka Kobayashi; Peter L Choyke
Journal:  Nanoscale       Date:  2015-10-07       Impact factor: 7.790

8.  Near infrared photoimmunotherapy in the treatment of pleural disseminated NSCLC: preclinical experience.

Authors:  Kazuhide Sato; Tadanobu Nagaya; Peter L Choyke; Hisataka Kobayashi
Journal:  Theranostics       Date:  2015-03-19       Impact factor: 11.556

9.  Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model.

Authors:  Kazuhide Sato; Peter L Choyke; Hisataka Kobayashi
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

10.  Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.

Authors:  Kimihiro Ito; Makoto Mitsunaga; Takashi Nishimura; Hisataka Kobayashi; Hisao Tajiri
Journal:  Oncotarget       Date:  2016-03-22
View more
  11 in total

1.  Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT.

Authors:  Takashi Nishimura; Makoto Mitsunaga; Kimihiro Ito; Hisataka Kobayashi; Masayuki Saruta
Journal:  Gastric Cancer       Date:  2019-07-13       Impact factor: 7.370

2.  Orthotopic Breast Cancer Model to Investigate the Therapeutic Efficacy of Nanobody-Targeted Photodynamic Therapy.

Authors:  Marion M Deken; Shadhvi S Bhairosingh; Alexander L Vahrmeijer; Sabrina Oliveira
Journal:  Methods Mol Biol       Date:  2022

3.  An Integrin-Targeted, Highly Diffusive Construct for Photodynamic Therapy.

Authors:  Oliver J Klein; Hushan Yuan; Nicholas H Nowell; Charalambos Kaittanis; Lee Josephson; Conor L Evans
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

4.  Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin.

Authors:  Yuko Nishinaga; Kazuhide Sato; Hirotoshi Yasui; Shunichi Taki; Kazuomi Takahashi; Misae Shimizu; Rena Endo; Chiaki Koike; Noriko Kuramoto; Shota Nakamura; Takayuki Fukui; Hiroshi Yukawa; Yoshinobu Baba; Mika K Kaneko; Toyofumi F Chen-Yoshikawa; Hisataka Kobayashi; Yukinari Kato; Yoshinori Hasegawa
Journal:  Cells       Date:  2020-04-20       Impact factor: 6.600

5.  Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.

Authors:  Yoshitaka Isobe; Kazuhide Sato; Yuko Nishinaga; Kazuomi Takahashi; Shunichi Taki; Hirotoshi Yasui; Misae Shimizu; Rena Endo; Chiaki Koike; Noriko Kuramoto; Hiroshi Yukawa; Shota Nakamura; Takayuki Fukui; Koji Kawaguchi; Toyofumi F Chen-Yoshikawa; Yoshinobu Baba; Yoshinori Hasegawa
Journal:  EBioMedicine       Date:  2020-01-23       Impact factor: 8.143

Review 6.  Antibody-drug conjugates: Recent advances in linker chemistry.

Authors:  Zheng Su; Dian Xiao; Fei Xie; Lianqi Liu; Yanming Wang; Shiyong Fan; Xinbo Zhou; Song Li
Journal:  Acta Pharm Sin B       Date:  2021-04-06       Impact factor: 11.413

7.  A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.

Authors:  Xinning Wang; Rongcan Sun; Jing Wang; Jing Li; Ethan Walker; Aditi Shirke; Gopolakrishnan Ramamurthy; Lingpeng Shan; Dong Luo; Lauren Carmon; James P Basilion
Journal:  Theranostics       Date:  2022-02-21       Impact factor: 11.556

8.  Real-time cancer detection with an integrated lensless fluorescence contact imager.

Authors:  Efthymios P Papageorgiou; Hui Zhang; Simeon Giverts; Catherine Park; Bernhard E Boser; Mekhail Anwar
Journal:  Biomed Opt Express       Date:  2018-07-09       Impact factor: 3.732

9.  Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.

Authors:  Marion M Deken; Marta M Kijanka; Irati Beltrán Hernández; Maxime D Slooter; Henriette S de Bruijn; Paul J van Diest; Paul M P van Bergen En Henegouwen; Clemens W G M Lowik; Dominic J Robinson; Alexander L Vahrmeijer; Sabrina Oliveira
Journal:  J Control Release       Date:  2020-04-21       Impact factor: 9.776

10.  Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer.

Authors:  Haruka Yamaguchi; Namfon Pantarat; Takamasa Suzuki; Andreas Evdokiou
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.